cyrilzakka/clinical-trials huggingface dataset:
Review and Assessment of Network Meta-analyses for Knowledge Uptake Study

This randomized controlled trial will assess the interpretability of the rank-heat plot for presenting the results of network meta-analysis in comparison to SUCRA (surface under the cumulative ranking) plots which are suggested to present one of the best ranking statistics.

Clinicians are responsible for making decisions to improve health outcomes. When available, clinicians should use the results of a knowledge synthesis, such as systematic reviews and meta-analyses, to inform decision-making. Pairwise meta-analyses are limited, however, by the availability of RCTs that directly compare interventions. This is troublesome for knowledge users who require results from comparisons of multiple interventions to inform decision-making. To address this concern, the use of network meta-analyses (NMAs) is increasing in healthcare the literature. NMAs are a useful tool because they can summarize results from numerous studies and interventions. It is unclear how NMA results should be presented to increase the likelihood of clinicians understanding and using the results to improve health outcomes. Thus, a randomized controlled trial of NMA plots will be conducted. Participants will be randomized to either the rank-heat plot (intervention) or SUCRA plots (control) that present the same NMA results of a study that explored the effectiveness of quality improvement interventions for falls prevention. Outcomes will be ascertained via an online survey. The RCT will take place in an online environment and will require each participant to partake in a single session. This study will help guide best practices for the presentation of reviews to improve the uptake and use of NMA.

Eligibility Criteria:
Inclusion Criteria:

* Clinicians must be accredited to practice in Canada and working (full- or part-time) as a family physician or general internist.

Exclusion Criteria:

* Unable to read and understand English;
* No access to the internet;
* Read, co-authored or peer-reviewed the study: "Quality Improvement strategies to Prevent Falls in the Elderly: A systematic review and network meta-analysis" (manuscript in preparation).
Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium

Medico-economic study of Newborn screening of Spinal Muscular Atrophy

The aim of this project is to demonstrate the feasibility and the medico-economic impact of a spinal muscular atrophy neonatal screening in a European country. We propose a 3-year-neonatal screening program in Southern Belgium (Wallonia-Brussels Federation) where there is 59.000 newborns/year, among whom 6 are affected by spinal muscular atrophy.

Eligibility Criteria:
Inclusion Criteria:

* All newborns in southern Belgium

Exclusion Criteria:

* Newborns whose parents refuse screening
Optimal Nutritional Palliation of Obstructed GEJ Cancer

The main goal of this trial is to assess whether it's feasible to conduct a larger, full-scale study comparing the use of gastrostomy (g-tubes) and stents in patients with unresectable cancer of the stomach and/or esophagus, and to evaluate their impact on patients' quality of life. Additional objectives include examining the rates of complications, the need for additional treatments, and the total number of hospital days over a three-month period.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years of age and older who are scheduled to undergo an esophageal stent or g-tube insertion for palliation in the context of an obstructing metastatic or unresectable gastroesophageal cancer.

Exclusion Criteria:

* Patients under the age of 18 years.
* 2. Stent or g-tube prior to enrolment.
Modified Magill Forceps Facilitating Nasal Intubation for Children Undergoing Dental Operations

compare between Magill forceps and modified pediatric Magill forceps for nasotracheal intubation (which method is easier and better?).

Group A One hundred and ten patients for whom modified pediatric Magill forceps was used to assist nasotracheal intubation.

Group B One hundred and ten patients for whom Magill forceps was used to assist nasotracheal intubation.

For each patient, intubation time, number of intubation attempts, hypoxia (recognized when oxygen saturation decreases below 94%), pharyngeal trauma, and need for corkscrewing will be recorded.

Eligibility Criteria:
Inclusion Criteria:

* Patients with the American Society of Anesthesiology physical status of 1 or 2
* Age 4 to 8 years old.
* Elective dental surgeries.

Exclusion Criteria:

* Parental refusal to consent (absolute contraindication),
* Patients with aspiration risk.
* Known upper airway abnormalities.
* Those having difficult airway.
The Effect of Nature-Based Music Concert on Intensive Care Patients

Purpose: This study was planned to determine the effect of nature-based music recital on pain and physiological parameters in intensive care patients.

Design: This research will be conducted as a pre-test post-test randomized controlled intervention study. Patient Information Form, Numerical Pain Scale and Physiological Parameters Tracking Form will be used as data collection forms.

H1: Nature-based music recital has an effect on pain level

H2: Nature-based music recital has an effect on physiological parameters


Eligibility Criteria:
Inclusion Criteria:

* Being 18 years or older
* Having orientation to place and time
* No communication (visual, auditory) barriers
* No neuromuscular blockade with medication
* Not applying nerve block,
* Not having peripheral neuropathy or quadriplegia
* Sedation level 1, 2, 3 and 4 according to the Ramsey Sedation Scale (RSS)

Exclusion Criteria:

* Glasgow Coma Scale score below 13 points
* Being diagnosed with a psychiatric disease
* Having dementia/brain dysfunction
* Having a hearing-related anomaly or health problem
* The patient has not undergone any painful procedure within the last hour.
* Sedation level should be 5 and 6 according to RSQ
Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds

The primary objective of this study is to detect differences in anti-S. aureus antibody assays (IgM, IgA, IgG and its subclasses) between (1) a group of patients with bacteremia due to a chronic wound (cases) and (2) a group of patients with localized chronic wound infections (control).

Secondary objectives include:

* To propose a diagnostic marker of bacteraemia based on the detection of anti-S. aureus by xMAP technology
* To evaluate the kinetics of the humoral immune response to S. aureus in patients with bacteraemia
* To evaluate the virulence of S. aureus isolated from chronic, infected wounds
* To enrich the Nîmes University Hospital biobank
* To evaluate the prevalence of different antibodies within each group

Eligibility Criteria:
Inclusion Criteria:

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* The patient is available for 6 months of follow up
* Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals
* inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed.

Controls:

* Absence of bacteriemia

Cases:

* Presence of bacteriemia

Exclusion Criteria:

* The patient is participating in another study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* The patient is pregnant, parturient, or breastfeeding
* The patient does not have a chronic wound
* Patient with grand 1 ulcer
* Patient's wound/ulcer is not infected
* Patient's would/ulcer is infected, but not involving S. aureus
Weight Change Among Users of Three Progestin-Only Methods of Contraception Over a 12-Month Time Period

The purpose of this study is to learn whether women who use progestin-only methods of birth control such as the contraceptive implant (Implanon), the levonorgestral-releasing IUS (Mirena), or depot medroxyprogesterone acetate(DMPA) will experience weight change compared to women using the non-hormonal copper IUC (ParaGard).

The investigators primary hypothesis is that users of DMPA will gain excess weight and increase their BMI above the copper-IUC users; secondarily, the investigators will compare users' data in the LNG-IUC and ENG implant groups to the copper-IUC group.


Eligibility Criteria:
Inclusion Criteria:

* Patients enrolled in CHOICE between the ages of 18 and 45 who consented to future studies
* Chose levonorgestrel-releasing IUD, copper IUD, the implant, or DMPA as their CHOICE baseline method
* Has baseline height and weight data collected from the on-campus enrollment site
* Able to come back to the on-campus enrollment site for consent process and enrollment activities

Exclusion Criteria:

* Recent history of DMPA use before starting their baseline CHOICE method
* Used current method for less than 11 months or more than 12 months and three weeks
CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

Non - small cell lung cancer ( NSCLC ) accounts for more than 80% of lung cancer. The main treatment for early stage patients is surgical resection, but about 30% -70% patients will relapse. Postoperative chemotherapy is the major systemic treatment for surgical resection NSCLC patients. However, data show only 5-10% improvement in overall survival with systemic adjuvant chemotherapy. It is necessary to further improve the survival time of patients with lung cancer. Biological treatment is becoming a new treatment modality for Cancer following with surgery, radiotherapy and chemotherapy, and has been confirmed as an effective adjuvant treatment in comprehensive cancer treatment. Cytokine induced killer cells ( CIK) characterized as fast amplification, strong anti-cancer activity and broad anti-tumor spectrum is most widely used and thought to be the first choice for the new generation of anti-tumor adoptive immunotherapy. This Phase II study is investigating the efficacy of Autologous Cytokine-Induced Killer Cell Transfusion plus Chemotherapy as adjuvant therapy for stage IB-IIIA NSCLC.


Eligibility Criteria:
Inclusion Criteria:

1. Stage IB-IIIA post-surgery NSCLC patients with histologically confirmed.
2. with an Eastern CooperativeOncology Group performance status of 0 or 1,
3. at least 18 years of age
4. adequate bone marrow reserve and organ function including calculated creatinine clearance 45 mL/min based on the standard Cockcroft and Gault formula
5. patients had fully recovered from its acute effects.

Exclusion Criteria:

1. HIV positive
2. autoimmune disease
3. immune deficiency disorder
4. organ transplantation
5. received high dose glucocorticoid or other immune depressant within 4 weeks
6. active clinically serious infections (\> grade 2 NCI-CTC version 3.0)
7. life threatening medical condition
Clinical Trial of Factor XIII (FXIII) Concentrate

Congenital deficiency of Factor XIII is a rare but potentially life threatening disorder. It is inherited in an autosomal recessive fashion. Infusion of Factor XIII has proved to be useful for prevention and treatment of bleeding episodes, especially of spontaneous intracranial bleedings. In this study, Fibrogammin P will be given to patients with congenital Factor XIII deficiency and congenital/acquired FXIII deficiency to prevent bleeding and to treat established bleeding episodes. For Factor XIII prophylaxis to prevent hemorrhages, the dosage will depend on the weight of the subject. The frequency of Factor XIII administration will be determined by the factor's circulating half-life. During the first month only, a Factor XIII pharmacokinetic study will be determined over a 4-week period. Safety data will include accrual of information on viral safety, liver function, complete blood counts and adverse events. Historical data concerning spontaneous bleeds will be collected whenever possible two years prior to treatment with Fibrogammin P.


Eligibility Criteria:
Inclusion Criteria:

* Patients may be of either sex or age. Children and newborn infants are specifically included in this study.
* Patient must have documented congenital Factor XIII deficiency
* Patient or legal guardian must sign informed consent
* Patients who have negative serology for hepatitis B should receive Hepatitis B vaccination.

Exclusion Criteria:

* Patient has acquired Factor XIII deficiency
A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

The main purpose of study is to compare different formulations of LY3410738 under fasting condition by looking at the amount of the study drug, LY3410738, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. The study will also access the effect of standard low-fat meal and esomeprazole (Proton Pump Inhibitor) on LY3410738. Safety and tolerability of LY3410738 will also be evaluated. For each participant, the total duration of the study will be 56 days for Groups 1 and 2 and up to 61 days for Groups 3 and 4, including screening.


Eligibility Criteria:
Inclusion Criteria:

* Must have Body mass index (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m\^2), inclusive.
* Male and female participants in good health, determined by no clinically significant findings from medical history, 12-lead Electrocardiogram (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator.
* Female participants of non-childbearing potential and male participants who follow standard contraceptive methods.
* Must have comply with all study procedures, including the 3-night stay at the Clinical Research Unit (CRU) and follow-up phone call.

Exclusion Criteria:

* History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor.
* Positive serologic test for hepatitis B surface antigen (HBsAg), hepatitis B virus immunoglobulin M (HBV IgM) core antibody, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody at Screening.
* Positive polymerase chain reaction (PCR) test for COVID-19 at Screening.
* Known ongoing alcohol and/or drug abuse within 2 years prior to Screening.
* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
* Have previously received LY3410738 in any other study investigating LY3410738, within 30 days prior to Day 1.
* Have history of a major surgical procedure within 30 days prior to Screening.
A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone

The purpose of this study is to evaluate the effect of steady-state (constant concentration of medication in the blood) TMC435 (150 mg, once a day) on the steady state pharmacokinetics (what the body does to the medication) of R- and S-methadone.

This is an open label (all people know the identity of the intervention) drug-drug interaction (TMC435 versus methadone) study. Approximately 12 hepatitis C virus-negative opioid-dependent participants on stable maintenance therapy (for at least 30 days before screening) will be enrolled in the study. The study will consist of 3 phases: 1) Run-in phase: during this phase, participants will take individualized (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily) dose of methadone from Day -14 (14 days before the first intake of TMC435) till Day -1 (1 day before the first intake of TMC435), which will be supervised by the medical staff. 2) 7 days treatment phase: during this phase, the participants will take 150 mg dose of TMC435 once daily from Day 1 to Day 7 orally (by mouth) plus the individualized dose of methadone which will be supervised by the medical staff. 3) Follow-up phase: during this phase, the participants will continue to take only the individualized dose of methadone for 30-32 days. Safety evaluations will include assessment of adverse events, clinical laboratory tests, cardiovascular safety, physical examination and alcohol breath test. The total study duration will be of 22 days excluding screening and follow-up phase.

Eligibility Criteria:
Inclusion Criteria:

* Receiving once daily oral methadone maintenance therapy at a stable individualized dose of 30 to 130 mg once daily for at least 30 days prior to screening
* Agreeing not to change the current methadone dose from screening until Day7 included and to have a daily observed and documented methadone intake from Day-14 until Day8 and to have a daily observed and documented TMC435 intake from Day1 until Day 7
* Having obtained approval from his/her addiction physician for participation in the trial and addiction physician agrees to provide medical care for the volunteer after discharge from the testing facility

Exclusion Criteria:

* No female of childbearing potential, except if using effective birth control methods during the trial and for at least 30 days after the end of the treatment period
* No positive testing for drugs of abuse
* No positive testing for Hepatitis A, B and C and for HIV1 and 2
* Impaired liver disease or other clinically relevant diseases
Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).

PURPOSE: This phase II trial is studying the side effects of giving fludarabine together with busulfan and antithymocyte globulin followed by donor stem cell transplant and to see how well it works in treating patients with multiple myeloma that has not responded to treatment.

OBJECTIVES:

Primary

* To study the toxicity of reduced intensity conditioning comprising fludarabine phosphate, busulfan, and anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed multiple myeloma.

Secondary

* To study the tumor response in these patients.
* To study the incidence of acute or chronic graft-versus-host disease in these patients.
* To study the incidence of infectious complications in these patients.
* To study relapse- or progression-free and overall survival of these patients.
* To study the biological mechanisms (i.e., taking graft, immunological recovery, antitumor activity, and chimerism).

OUTLINE: This is a multicenter study.

Patients receive reduced intensity conditioning comprising fludarabine IV on days -5 to -1, oral busulfan on days -4 and -3, and anti-thymocyte globulin IV on days -2 and -1. Patients undergo allogeneic hematopoietic stem cell transplantation on day 0.

After completion of study therapy, patients are followed every month for 6 months and then every 3 months for 1½ years.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of multiple myeloma, meeting 1 of the following criteria:

  * Stage I disease with a bone lesion
  * Stage II or III disease meeting any of the following criteria:

    * Elevated beta-2 microglobulin
    * Deletion of chromosome 13
* Refractory or relapsed disease
* Presence of an evaluable monoclonal component
* Must have achieved reduction of primary tumor after receiving prior intensified chemotherapy with high-dose melphalan and cyclosporine with autologous transplantation
* HLA identical family donor available

  * Bone marrow transplantation is allowed in case hematopoietic stem cell collection fails

PATIENT CHARACTERISTICS:

* Karnofsky 70-100%
* No contraindications to allogeneic transplantation
* No contraindications to drugs used in conditioning regimen
* No psychiatric illness
* No other cancer within the past 5 years except basal cell skin cancer or epithelioma in situ of the cervix
* No serious and uncontrolled infection
* Not pregnant or nursing
* Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 1 month since participation in another prior clinical trial
Spectral Characteristics of Memory Transformation

Sometimes, it is necessary to re-learn a previously learned movement behavior, for example, a bad posture during the golf drive or while playing the piano. Unlearning or relearning an intensively trained behavior is particularly important if the behavior is hampering recovery, for example, in chronic pain or after a stroke. With this pilot study, the brain mechanisms that control the change of pre-existing stable memories of a motor skill will be tested with electroencephalography (EEG). Non-invasive brain stimulation will be used to modulate these brain mechanisms and test if it is possible to change the pre-existing motor memory and the learning of a new motor skill.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years or older (2/3 of the final sample will be ≥60years of age)
* No previous stroke, brain tumor, neurodegenerative disease, or trauma to the head
* Ability to give consent for study participation
* who have access to a personal computer with internet

Exclusion Criteria:

* • Pregnancy

  * Inability to use all ten fingers to type on a standard computer keyboard
  * Uncorrected vision, hindering perception of visual cues presented on a standard computer screen
  * Medication use at the time of study that may interfere with learning or the effect of tACS, including but not limited to carbamazepine, flunarizine, sulpiride, rivastigmine, dextromethorphan;
  * Neuromuscular disorders affecting hand and finger movements necessary for 10-finger keyboard typing
  * Presence of neurological or psychiatric disorders
  * Presence of scalp injury or disease
  * Prior history of seizures
  * Prior intracranial surgery
  * Prior brain radiotherapy
  * Prior history of intracranial tumor, intracranial infection, or cerebrovascular malformation
  * Metal in head or neck
  * Contraindications to MRI (such as severe claustrophobia, implanted medical devices)